• Explore /
  • Poster
  • / Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.

Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.

Abstract Poster

Authors

Breelyn Wilky

Breelyn A. Wilky

Sylvester Comprehensive Cancer Center, Miami, FL

Breelyn A. Wilky , Priya Kumthekar , Robert Wesolowski , Jimmy J. Hwang , Steven I. Park , Igor Proscurshim , Guojun Yuan , Christopher D Dupont , Olga Shebanova , Jean-Marie Cuillerot , Edward Dow , Jeffrey J. Raizer , Carleen Gentry , Ainsley Ross , Elise Drouin , Nicholas Wilson , John M. Goldberg , Jennifer Buell , Robert Benjamin Stein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT02694822

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3075)

DOI

10.1200/JCO.2018.36.15_suppl.3075

Abstract #

3075

Poster Bd #

289

Abstract Disclosures

Similar Posters

First Author: Omid Hamid

First Author: Patrick Alexander Ott

First Author: Margaret K. Callahan

First Author: Funda Meric-Bernstam